成本效益指南。澳大利亚制造商的经验。 - Suppr

Suppr

超能文献

Cost-effectiveness guidelines. The experience of Australian manufacturers.

作者信息

Gorham P

机构信息

Pfizer Pty Ltd, West Ryde, New South Wales, Australia.

出版信息

Pharmacoeconomics. 1995 Nov;8(5):369-73. doi: 10.2165/00019053-199508050-00001.

DOI:10.2165/00019053-199508050-00001

PMID:10160071

Abstract

摘要

相似文献

Cost-effectiveness guidelines. The experience of Australian manufacturers.成本效益指南。澳大利亚制造商的经验。

Pharmacoeconomics. 1995 Nov;8(5):369-73. doi: 10.2165/00019053-199508050-00001.

Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?澳大利亚药品成本效益研究指南：回旋镖的薄刃一端？

Pharmacoeconomics. 1992;1(Suppl 1):61-9. doi: 10.2165/00019053-199200011-00014.

Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.基于购买方总预算的药品风险分担协议分析

Health Econ. 2005 Aug;14(8):793-803. doi: 10.1002/hec.976.

Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?聚焦药物经济学活动：报销还是药物生命周期？

Curr Med Res Opin. 2004;20(2):181-8. doi: 10.1185/030079903125002838.

Industry comment on the 1995 revised Australian pharmacoeconomic guidelines.

Pharmacoeconomics. 1996 Apr;9(4):353-6. doi: 10.2165/00019053-199609040-00008.

[Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].新药的成本效益影响报销决策，但仍有改进空间。

Ned Tijdschr Geneeskd. 2010;154:A958.

Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.荷兰和苏格兰孤儿药申报监管建议回顾：重点关注潜在的药物经济学评估。

Clin Ther. 2010 Aug;32(9):1651-61. doi: 10.1016/j.clinthera.2010.08.006.

[The French medecine pricing committee and the medicine economic policy: Rules and competences].[法国药品定价委员会与药品经济政策：规则与权限]

Ann Pharm Fr. 2017 Sep;75(5):359-372. doi: 10.1016/j.pharma.2017.04.001. Epub 2017 May 15.

Using pharmacoeconomic analysis to make drug insurance coverage decisions.运用药物经济学分析进行药品保险覆盖范围决策。

Pharmacoeconomics. 1998 Jan;13(1 Pt 2):119-26. doi: 10.2165/00019053-199813010-00011.

Implications of the Australian guidelines for the United States.

Health Aff (Millwood). 1992 Winter;11(4):202-6. doi: 10.1377/hlthaff.11.4.202.

引用本文的文献

Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo.低剂量巯嘌呤联合别嘌醇：这一有效组合的过去、现在与未来。

Dig Dis Sci. 2022 Dec;67(12):5382-5391. doi: 10.1007/s10620-022-07719-x. Epub 2022 Oct 15.

Cost of pharmacological care of the elderly: implications for healthcare resources.老年人药物治疗的成本：对医疗资源的影响。

Drugs Aging. 2003;20(4):253-61. doi: 10.2165/00002512-200320040-00002.

Using economic evaluations to make formulary coverage decisions. So much for guidelines.利用经济评估来做出药品目录覆盖范围的决策。关于指南就说这么多。

Pharmacoeconomics. 2000 Jul;18(1):55-62. doi: 10.2165/00019053-200018010-00006.

本文引用的文献

The emerging government requirement for economic evaluation of pharmaceuticals.政府对药品经济评估的新要求。

Pharmacoeconomics. 1994;6 Suppl 1:42-50. doi: 10.2165/00019053-199400061-00012.

'This house believes that pharmacoeconomic analysis should be mandated by governments rather than left to market forces'.本院认为药物经济学分析应由政府强制推行，而非任由市场力量决定。

Pharmacoeconomics. 1994 Oct;6(4):352-7. doi: 10.2165/00019053-199406040-00002.

Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.作为补贴决策辅助手段的经济分析：澳大利亚药品指南的制定

Pharmacoeconomics. 1992 Jan;1(1):54-67. doi: 10.2165/00019053-199201010-00010.

Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?澳大利亚药品成本效益研究指南：回旋镖的薄刃一端？

Pharmacoeconomics. 1992;1(Suppl 1):61-9. doi: 10.2165/00019053-199200011-00014.

Choosing from the health care reform menu.从医疗保健改革菜单中进行选择。

J Am Health Policy. 1991 Nov-Dec;1(3):23-7.

Basing prescription drug payment on economic analysis: the case of Australia.基于经济分析的处方药支付：以澳大利亚为例。

Health Aff (Millwood). 1992 Winter;11(4):191-6. doi: 10.1377/hlthaff.11.4.191.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验